In a specific strain of rats with diabetes, a 7-day course of an SGLT2 inhibitor improves the ability to switch between burning fat and glucose for energy, as shown by changes in respiratory gas...

We analyzed the available evidence on SGLT2 inhibitors and metabolic flexibility in Zucker diabetic fatty rats, and what we’ve found so far leans toward the idea that these drugs may help improve the body’s ability to switch between burning fat and glucose. In one study, a 7-day course of an SGLT2 inhibitor was linked to better metabolic switching in this specific strain of rats, as measured by changes in respiratory gas exchange and reduced fat accumulation inside cells [1]. This suggests the rats were more able to adapt their energy use based on what fuel was available — a trait known as metabolic flexibility. We did not find any studies that contradicted this finding. However, the evidence is limited to just one assertion, and it only applies to Zucker diabetic fatty rats — a genetically modified model used to study type 2 diabetes. We don’t know if these results would apply to other animals, humans, or longer treatment periods. The study measured outcomes like gas exchange and fat buildup in cells, which are indicators of metabolic flexibility, but they are not direct measures of how the body regulates energy in real-world conditions. Our current analysis shows a pattern of support, but we can’t say whether this effect is strong, lasting, or universal. More studies would be needed to understand how consistent this result is, what dose or duration works best, and whether similar changes happen in other models of metabolic disease. For now, if you’re looking at this research to understand how SGLT2 inhibitors might affect energy use in diabetic models, the one study we reviewed suggests a possible benefit — but it’s just one piece of a much larger puzzle.